Isturisa® continues to show promise in Cushing’s disease
New Phase III trial results show 81 percent of Cushing’s disease patients who received Isturisa® (osilodrostat) had sustained normalisation of mean urinary free cortisol levels.
List view / Grid view
New Phase III trial results show 81 percent of Cushing’s disease patients who received Isturisa® (osilodrostat) had sustained normalisation of mean urinary free cortisol levels.
The FDA has approved Isturisa for Cushing’s disease treatment after it demonstrated significant efficacy in clinical trials.